Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06578559 |
Title | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET) |
Acronym | BRICKET |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Gruppo Oncologico del Nord-Ovest |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | ITA |